Premium
An immediate hemolytic reaction induced by repeated administration of oxaliplatin
Author(s) -
Chen Vivien M.Y.,
Thrift Karen M.,
MorelKopp MarieChristine,
Jackson David,
Ward Christopher M.,
Flower Robert L.
Publication year - 2004
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2004.03111.x
Subject(s) - hemolysis , oxaliplatin , band 3 , antibody , hemolytic anemia , medicine , epitope , chemotherapy , immunology , pharmacology , chemistry , membrane protein , membrane , biochemistry , cancer , colorectal cancer
BACKGROUND: Platinum‐based chemotherapy agents have been associated with potentially fatal acute immune‐mediated hemolytic anemia. The target antigen, cause of the positive direct antiglobulin test (DAT) and mechanism of hemolysis have been the subject of controversy. CASE REPORT: We report a patient who developed a DAT‐positive hemolytic episode after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin. Standard pretransfusion testing was uncomplicated; however, after infusion, the serum was no longer compatible with the transfused units and a strong (4+) panreactive IgG antibody was detected. RESULTS: The patient's serum from 10 days after the episode, only when therapeutic concentrations of oxaliplatin were added, reacted with all RBCs tested using the indirect antiglobulin test (IAT) (3+). The effect was retained with a purified IgG fraction and almost eliminated with IgG‐depleted serum. Immunoprecipitation analysis revealed a band with the molecular weight of the Band 3 anion channel only in the presence of the patient's serum and oxaliplatin. CONCLUSION: Our investigations indicated that oxaliplatin interacted with both an IgG antibody and a RBC membrane epitope probably located on the Band 3 anion channel.